earnings
confidence high
sentiment positive
materiality 0.70
Establishment Labs Q3 revenue $38.2M (+31.7% YoY); tightens 2022 guidance to $158-162M
ESTABLISHMENT LABS HOLDINGS INC.
2022-Q3 EPS reported
-$2.53
revenue$117,887,000
- Q3 revenue $38.2M, up 31.7% YoY (37.7% constant currency); net loss $10.5M vs $9.0M in Q3 2021.
- Gross margin improved to 68.1% from 67.6%; operating expenses rose 27.5% to $36.6M.
- 2022 revenue guidance tightened to $158-162M from $155-165M; constant-currency growth 30-33% YoY.
- Cash balance $65.3M as of Sep 30; expects Mia Femtech launch and China approval in 1H 2023.
- Plans to submit Motiva Implants for U.S. FDA approval in Q4 2022; all U.S. IDE trial cohorts enrolled.